Related Experiment Video
Updated: Aug 21, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: an intriguing clinical observation
1Unit of Bone and Soft Tissue Oncology, Division of Oncology, The Tel-Aviv Sourasky Medical Center, 6 Weizmann Street, Tel-Aviv 64239, Israel. merimsky@zahav.net.il.
Abstract:
The emerging anti-cancer approach is based on combining a 'traditional' cytotoxic drug with a 'signaling' blocking agent. Such combination, if designed and applied properly, may increase selectivity towards tumor cells. The use of such combinations requires smart planning and choice of the drugs to be combined, their proper dosing as well as correct sequence and schedule of application. The combination of the anti-metabolite gemcitabine and the mTOR blocker, rapamycin, has achieved an impressive response in a patient with metastatic leiomyosarcoma.
Insights
Combining cytotoxic chemotherapy with targeted therapy offers a promising anti-cancer strategy. This approach, exemplified by gemcitabine and rapamycin, showed significant results in treating metastatic leiomyosarcoma.
Area of Science:
- Oncology
- Pharmacology
Background:
- Emerging anti-cancer strategies involve combining cytotoxic drugs with signaling pathway inhibitors.
- Optimizing drug combinations requires careful consideration of drug choice, dosing, and scheduling for enhanced tumor selectivity.
Observation:
- A patient with metastatic leiomyosarcoma was treated with a combination therapy.
- The treatment regimen involved gemcitabine, an anti-metabolite, and rapamycin, a mammalian target of rapamycin (mTOR) inhibitor.
Findings:
- The combination of gemcitabine and rapamycin demonstrated an impressive clinical response in the patient.
- This suggests the potential efficacy of combining chemotherapy with mTOR inhibition for advanced cancers.
Implications:
- This combination therapy may improve treatment outcomes for metastatic leiomyosarcoma.
- Further research into optimized combination regimens could enhance anti-cancer selectivity and efficacy.
